Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Andrew Carr was honoured in the 2025 King’s Birthday Honours List being awarded an MBE for services to Orthopaedic Research and Training.

Professor Andrew Carr

Professor Carr has had a distinguished career, combining clinical practice, teaching, research, and leadership roles. His research has significantly influenced the management of surgical patients, including pioneering the development and evaluation of surgical implants and technologies like the Oxford partial knee replacement, that has been implanted in over 2 million patients worldwide, and outcome scores that have been used to assess patient health globally. He has focused on improving the infrastructure for surgical trials and led the use of placebo surgery controls, decommissioning ineffective operations.

Professor Carr has been a strong promoter of interdisciplinary research, founding the Botnar Institute for Musculoskeletal Sciences and directing a NIHR Biomedical Research unit. He has held leadership positions in healthcare organisations and advisory roles in higher education. He has received numerous national and international awards in recognition of his contributions.

Andrew said: 'It was a huge surprise to receive this award. It recognises the work of many colleagues, collaborators and students who have been very supportive throughout my career. I am enormously appreciative to them all. I am especially pleased that orthopaedic research has been recognised and am grateful to the commitment and support of patients and funders.'

Head of Department Jonathan Rees said: 'I was so delighted to see Andy honoured this year in the Kings Birthday Honours list. Andy’s contribution to orthopaedic research and teaching has been profound both in Oxford and internationally. We have all benefited here in NDORMS from Andy’s strategic vision over the years and I am sure you will join with me in congratulating him on the endorsement of his contributions by His Majesty.'

Similar stories

Could patients with common fractures recover without routine hospital follow-up?

The FASTER study will investigate whether thousands of people with common fractures can recover just as well with good-quality advice and rehabilitation guidance, without the need for routine hospital follow-up appointments.

Could the gut’s nervous system hold new clues to treating Crohn’s disease?

Researchers at the Kennedy Institute are investigating whether the nervous system within the gut could provide a new way to understand and ultimately treat Crohn’s disease.

NDORMS appoints a new Research Professor of Regulatory Innovation to help accelerate the development pipeline of new treatments

Lincoln Tsang has been appointed as the new John Climax Research Professor of Regulatory Innovation – a new role at NDORMS and the University of Oxford that brings global regulatory and legal expertise to our ambitions to transform and improve drug development pathways in order to help deliver safe and effective treatments to patients sooner. He will assume this role effective 2 January 2027.

Look Beyond My Skin: Your Psoriasis Could Help Us Understand Who Develops Psoriatic Arthritis

Adults with psoriasis across Europe are invited to take part in an online study aiming to identify who is at risk of developing psoriatic arthritis.

New PI Marie Pust aims to bring microbiome research closer to patients

We welcome Marie-Madlen Pust, who has joined the Kennedy Institute as a new Principal Investigator. Marie will establish a research group combining computational biology with targeted experimental microbiology to identify microbial drivers of chronic inflammatory disease that can be monitored (diagnostic potential) or modified (therapeutic potential).

Oxford EMCRF starts pioneering engineered nTreg trial for severe autoimmune disease

The Oxford Experimental Medicine Clinical Research Facility (EMCRF) has recruited its first patients into the CHILL trial, an early-phase study of an innovative cell therapy for severe autoimmune disease.